Ibyra 150 Tablets Ibyra 150 contains Olaparib Tablets 150 mg, a targeted anticancer medicine classified as a PARP (Poly ADP-Ribose Polymerase) inhibitor. It is used to treat certain types of ovarian, breast, pancreatic, and prostate cancers, particularly in patients with BRCA gene mutations or other homologous recombination repair (HRR) gene alterations. Olaparib works by preventing cancer cells from repairing damaged DNA, leading to their destruction while helping to slow disease progression. It should be used only under the supervision of an oncologist.